Mesenchymal Stem Cells and Clinical Application in Chronic Lung Diseases
Downloads
Mesenchymal stem cells are a multipotent mature non hematopoietic stem cells, with characteristics such as ability to self-renew and differentiate in mesodermal, ectodermal, and endodermal pathway. Mesenchymal stem cells also secrete cytokine and immunoreceptor which regulate micro environment in host tissues and angiogenic mediators which are able to improve damaged tissues. Mesenchymal stem cells are obtained from the human body by isolation, culture, proliferation, characterization, and/or differentiation originating from fat cells (adipose), periosteum tissue, and other tissues from the body. Mesenchymal stem cells can be obtained by autologous and allogenic way. Stem cell processing includes isolation, proliferation, differentiation, and temporary storage for clinical application adhering to good drug manufacturing practice. Approach to cell therapy and bioengineering in lung disease is rapidly developing in the last 10 years. In the current era of cell therapy and transplantation, a lot of research has been done to understand and develop mesenchymal stem cells as a therapeutic alternative, particularly in respiratory area.
Ningrum AP, Kurniawaty E. Peran Sel Punca Mesenkimal dalam Memperbaiki Kerusakan Parenkim Paru. Majority 2019; 8: 201–205.
Indonesia KKR. Peraturan Menteri Kesehatan Republik Indonesia Nomor 32 Tahun 2018 tentang Penyelenggaraan Pelayanan Sel Punca dan/atau Sel. 32, Indonesia, 2018.
Zakrzewski W, Dobrzyński M, Szymonowicz M, et al. Stem Cells: Past, Present, and Future. Stem Cell Res Ther 2019; 10: 68.
Health NI of. NIH Stem Cell Information. U.S. Department of Health & Human Services, https://stemcells.nih.gov/ (2016).
Purdon S, Glassberg MK. Multipotent Mesenchymal Stromal Cells and Lung Disease: Not Ready for Prime Time. Annals of the American Thoracic Society 2019; 16: 669–671.
MusiaÅ‚-Wysocka A, Kot M, Majka M. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies. Cell Transplant 2019; 28: 801–812.
Schilders KAA, Eenjes E, van Riet S, et al. Regeneration of the Lung: Lung Stem Cells and the Development of Lung Mimicking Devices. Respir Res 2016; 17: 44.
Wecht S, Rojas M. Mesenchymal Stem Cells in the Treatment of Chronic Lung Disease. Respirology 2016; 21: 1366–1375.
Gomez-Salazar M, Gonzalez-Galofre ZN, Casamitjana J, et al. Five Decades Later, Are Mesenchymal Stem Cells Still Relevant? Front Bioeng Biotechnol 2020; 8: 148.
Harrell CR, Sadikot R, Pascual J, et al. Mesenchymal Stem Cell-Based Therapy of Inflammatory Lung Diseases: Current Understanding and Future Perspectives. Stem Cells Int 2019; 2019: 4236973.
Pittenger MF, Discher DE, Péault BM, et al. Mesenchymal Stem Cell Perspective: Cell Biology to Clinical Progress. NPJ Regen Med 2019; 4: 22.
Portal SC. Clinical Trials: Lung Disease. The Stem Cells and Regenerative Medicine Online Community,https://stemcellsportal.com/clinical_trials_lung_disease.
Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal Stem Cell Engraftment in Lung is Enhanced in Response to Bleomycin Exposure and Ameliorates Its Fibrotic Effects. Proc Natl Acad Sci U S A 2003; 100: 8407–8411.
Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic Human Mesenchymal Stem Cells in Patients with Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. Chest 2017; 151: 971–981.
(GOLD) GI for COLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2021 Report). 2021.
Sun Z, Li F, Zhou X, et al. Stem Cell Therapies for Chronic Obstructive Pulmonary Disease: Current Status of Pre-Clinical Studies and Clinical Trials. J Thorac Dis 2018; 10: 1084–1098.
Huh JW, Kim S-Y, Lee JH, et al. Bone Marrow Cells Repair Cigarette Smoke-Induced Emphysema in Rats. Am J Physiol Lung Cell Mol Physiol 2011; 301: L255-66.
Gu W, Song L, Li X-M, et al. Mesenchymal Stem Cells Alleviate Airway Inflammation and Emphysema in COPD through Down-Regulation of Cyclooxygenase-2 Via p38 and ERK MAPK Pathways. Sci Rep 2015; 5: 8733.
Le Thi Bich P, Nguyen Thi H, Dang Ngo Chau H, et al. Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Treating Chronic Obstructive Pulmonary Disease: A Pilot Clinical Study. Stem Cell Res Ther 2020; 11: 60.
(GINA) GI for A. Global Strategy for Asthma Management and Prevention (2021 Update). Wisconsin, 2021.
Castro LL, Kitoko JZ, Xisto DG, et al. Multiple Doses of Adipose Tissue-Derived Mesenchymal Stromal Cells Induce Immunosuppression in Experimental Asthma. Stem Cells Transl Med 2020; 9: 250–260.
Cereta AD, Oliveira VR, Costa IP, et al. Emerging Cell-Based Therapies in Chronic Lung Diseases: What about Asthma? Front Pharmacol 2021; 12: 648506.
Cruz FF, Borg ZD, Goodwin M, et al. Systemic Administration of Human Bone Marrow-Derived Mesenchymal Stromal Cell Extracellular Vesicles Ameliorates Aspergillus Hyphal Extract-Induced Allergic Airway Inflammation in Immunocompetent Mice. Stem Cells Transl Med 2015; 4: 1302–1316.
Du Y-M, Zhuansun Y-X, Chen R, et al. Mesenchymal Stem Cell Exosomes Promote Immunosuppression of Regulatory T Cells in Asthma. Exp Cell Res 2018; 363: 114–120.
Copyright (c) 2021 Isti Mardiana Soetartio, Triya Damayanti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (